4.2 Article

Medical Management of Cushing Disease

期刊

NEUROSURGERY CLINICS OF NORTH AMERICA
卷 30, 期 4, 页码 499-+

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2019.05.007

关键词

Cabergoline; Cushing disease; Etomidate; Ketoconazole; Levoketoconazole; Metyrapone; Mifepristone; Mitotane

向作者/读者索取更多资源

Medical therapy for Cushing disease is primarily used to control hypercortisolism in patients whose disease persists or with recurrent disease after pituitary surgery, including those awaiting the salutary effects of radiation therapy. In can also be used to control hypercortisolism preoperatively, and in patients who decline surgery or whose tumor location is unknown. Steroidogenesis inhibitors, centrally acting agents, and glucocorticoid receptor antagonists are currently available to treat hypercortisolism, and several novel agents are in development. Given the absence of head-to-head clinical trials, choice between treatments has to be individualized based on careful consideration of patient, tumor, and disease characteristics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据